| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Photochlor (HTTP), a photodynamic therapy (PDT) agent, is a lipophilic, second-generation, chlorin-based photosensitizer. Upon IV administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration.
| ln Vitro |
Fluorescence pictures of 4T1 cells cultured in a solution containing 0.49 µg/mL GO-PEG, 1 µM HPPH (free HPPH), or a combination of 1 µM HPPH and 0.49 µg/mL GO-PEG for a duration of 24 hours. GO-PEG-HPPH and HPPH cellular absorption were investigated in 4T1 murine breast cancer cells. After giving cells equivalent quantities (1 µM) of GO-PEG-HPPH and free HPPH for a whole day, the cells were examined using confocal microscopy. Compared to cells treated with free HPPH, those treated with GO-PEG-HHPH displayed more pronounced fluorescent signals. In actuality, HPPH has very little fluorescence [1].
|
|---|---|
| ln Vivo |
Enhancing antitumor immunity while maintaining efficient control over primary tumor growth can be achieved by treating tumors with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen. In order to investigate this theory, a combination treatment plan was created. BALB/c mice bearing Colo26-HA tumors were given the HPPH-PDT regimen, which is known to improve antitumor immunity (0.4 μmoles/ kg HPPH) by irradiating the tumor with 665 nm light (a total dose of 48 J/cm2). The mice were given an injection of HPPH on the ninth day after they had been awake for nine days. The tumor was treated with a tumor control treatment regimen (irradiation with 665 nm light, total dose 132 J/cm2) on the tenth day following the first treatment [2].
|
| References |
|
| Additional Infomation |
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).
HPPH is a lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration. |
| Molecular Formula |
C39H48N4O4
|
|---|---|
| Molecular Weight |
636.822830200195
|
| Exact Mass |
636.367
|
| CAS # |
149402-51-7
|
| PubChem CID |
148160
|
| Appearance |
Light brown to black solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
980.8±65.0 °C at 760 mmHg
|
| Flash Point |
547.0±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.620
|
| LogP |
8.75
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
47
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
OC1=C2C(C)=C3C=C4C(CC)=C(C)C(C=C5C([C@H](C)OCCCCCC)=C(C)C(C=C6[C@@H](C)[C@H](CCC(=O)O)C(=C(C2=N3)C1)N6)=N5)=N4 |t:6,14,29,39|
|
| InChi Key |
PUUBADHCONCMPA-USOGPTGWSA-N
|
| InChi Code |
InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,42,44H,8-16H2,1-7H3,(H,45,46)/t21-,24?,26-/m0/s1
|
| Chemical Name |
3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~196.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5703 mL | 7.8515 mL | 15.7030 mL | |
| 5 mM | 0.3141 mL | 1.5703 mL | 3.1406 mL | |
| 10 mM | 0.1570 mL | 0.7852 mL | 1.5703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02119728 | WITHDRAWN | Drug: HPPH Device: Light Infusion Therapy™ Procedure: therapeutic conventional surgery |
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Verrucous Carcinoma of the Oral Cavity Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity |
Roswell Park Cancer Institute | 2017-01 | Phase 2 |
| NCT03090412 | TERMINATEDWITH RESULTS | Drug: HPPH Other: Laboratory Biomarker Analysis Drug: Photodynamic Therapy |
Stage I Oral Cavity Squamous Cell Carcinoma Stage II Oral Cavity Squamous Cell Carcinoma |
Roswell Park Cancer Institute | 2018-03-07 | Phase 2 |
| NCT01668823 | COMPLETED | Drug: HPPH Drug: photodynamic therapy Procedure: therapeutic bronchoscopy |
Adenocarcinoma of the Lung Large Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Squamous Cell Lung Cancer Stage 0 Non-small Cell Lung Cancer |
Roswell Park Cancer Institute | 2004-02 | Phase 1 |
| NCT00470496 | COMPLETED | Drug: HPPH Drug: photodynamic therapy Procedure: conventional surgery |
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Basal Cell Carcinoma of the Lip Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity |
Roswell Park Cancer Institute | 2006-10-19 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA